Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has established a collaboration with Charité – Universitätsmedizin Berlin to evaluate the combination of its vascular embolic agent EmboCept® S DSM 50 µm and immunotherapy.

As a first step of the collaboration, the parties are planning a study to explore the immune-modulating effect of EmboCept® S DSM 50 µm when administered in a preclinical research model of hepatocellular carcinoma.

“The establishment of this prestigious collaboration with a leading German research group at Charité Berlin is part of Magle’s continued efforts to improve patient impact by developing and extending the medical use of our existing DSM-based product line,“ says Justin Pierce, CEO of Magle Group.

EmboCept® S DSM 50 µm is a CE-marked medical device for vascular occlusion of liver and lung tumors. The product is based on Magle Group’s proprietary polymer technology, DSM® (Degradable Starch Microsphere), and is approved for sale in Europe, Singapore, Malaysia, Israel, and Argentina. Post-market studies are ongoing with the aim of expanding its therapeutic use.

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

Magle Group initiates collaboration with leading German university hospital to explore synergies between EmboCept® S DSM 50 µm and immunotherapies

© Modular Finance, source Nordic Press Releases